Get started
PharmaTher Holdings Ltd.PharmaTher Holdings Ltd.PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

PHRRF trade ideas

PHRRF - SUPPORT RESISTANCE PHRRF Stock ------------------ --Monthly support/resistance have drawn in red color, weekly in orange and daily in blue --Marked two support price in green and one resistance price in red -- RSI is in over bought zone , need to cool off --Last three days volumes are good --Try to break the monthly resistance price .80$, 3rd time --Multiple catalyst this year , see the below PPT for reference ( Slide - 6 ) www.pharmather.com --Can go above 1$ range --Good stock for long time hold --These are for my own log for future analysis , Thanks Govind
OTC:PHRRFLong
by catgovind
Pharma Patent Law Party Time!! $PHRRFSo here's my guess for the next short term bout of fun and awesome small cap volatility! Seriously though, I like how this company operates so far. Protective patents have been filed, they've already set up plenty of partnerships to get clinical trials rolling, and the blue-sky potential here is pretty staggering. No, really, it's suspiciously good. I'm obviously kinda dumb though, so it could just be a "stuck in my own thrall" kinda situation. Ok for starters, I'll admit that I don't care about the patent stuff. I'll explain why: I'm confident that the microneedle patch is protective enough that the whole issue of 'method of treatment' patents is negligible. But everyone is going to see "Clinical Trials for Big Disease! Big Yes!" Then they see it's for a generic drug and are all, "well that isn't how you print money!" and they scurry back into their dark abyss. Ok, so say it with me: " proprietary patch is patent protected." Don't worry, I'm totally gonna forget, too! But even aside from that, there is a (relatively-recent!) precedent set for patent protections in regards to "Methods of Treatment." It's a whole 'thing' that I'm not qualified to talk about, but I'm doing my own due diligence. Without looking though, I can say that a court case settled in 2018 is new by law standards, and new laws are frequently subject to challenges. For this reason, I'm gonna go ahead and anticipate a (temporary, brief) further drop in share price until everyone brushes up on the relevant patent cases. When everyone's homework gets turned in, I'm thinking we'll see $0.45USD. Idk, I really like when projected patterns line up with good fundamental markers- bonus points for ending on or near pretty, round numbers. I've gotta admit though, it's definitely feels like a stupid way to think, so it's probably dangerous to share the notion. Caveat stultus and all that. Regardless, the company still has a ridiculously small market cap when compared to other equivalent players in the psychedelic pharmaceutical space. Yeah, even after the recent gains. (To be fair, it could just mean that everyone else has much more room to fall.) Anyway! Let me know if I need to stop! :)
OTC:PHRRFLong
by pleasesendhel
Literally The Most Undervalued "Shroom Stock?"I mean look, I know it's all a bunch of speculative mumbo jumbo, but some of these other psychedelic companies have like, BILLION dollar market caps! That's crazy, right? I mean sure, they will certainly disrupt an incredibly-entrenched industry, but it's going to take time for that to happen... That said, I think there are going to be baby steps, which means they're going to work with what they know is effective in the "now." So yeah, ketamine. I'm not a huge fan either, but it's super difficult to ignore it's efficacy in the face of all the facts. I know it's contraindicated for certain individuals, but I still believe there's an avenue for success available for novel formulations. It all looks wacky and appears at first to be pseudoscience, but we're talking about research methods (like PanaceAI) that have been under development for years. It's crazy until it happens, and then it's useful. And it's more than icing on the cake that ketamine is a candidate for the treatment of a whole litany of movement disorders such as ALS. Iiii know, vile, evil drugs are bad and horrible. They'll certainly kill us all, as they always have. But seriously, look into a few things before you scoff at reality. "NMDA receptor antagonist," "parkinson's LID ketamine," "ketamine glutamate." Oh, I mentioned market caps. There's a fundamental reason to pay close attention here: as of right now (5/2/21), it's looking like a little north of $14 million USD. The company already had a pre-IND meeting with the FDA regarding their first Phase II trial, and as noted in the chart, the announcement was made on 4/20. For those that aren't aware, this means that the company will be permitted to commence their trials as soon as 5/21, provided that the FDA does not deny the IND request. 8 sites, up to 36 patients.. based on "no-brainer" data. Catalyst one. Let me know how wrong I am about this, please. I am begging you to give me a counterpoint here, because I've dug and dug and haven't found it yet.
OTC:PHRRFLong
by pleasesendhel